These data confirmed our perspective and were consistent with the results in ovarian cancer and non-small cell lung cancer [41], suggesting that patients with high expression of cGAS have better radiosensitivity, which may provide an additional significance for the clinical application of cGAS in GC therapy. This evidence concerns the gene CGAS and non-small cell lung carcinoma.